Bioxytran (BIXT) Non-Current Assets (2010 - 2026)
Bioxytran (BIXT) posted Non-Current Assets of $152206.0 for Q1 2026, up 4.91% sequentially from $145087.0 in Q4 2025, and up 15.57% YoY from $131704.0 in Q1 2025.
Bioxytran (BIXT) Non-Current Assets (2010 - 2026) Analysis & Trends
Bioxytran has reported Non-Current Assets for 16 years, with the latest figure at $152206.0 in Q1 2026.
- Quarterly Non-Current Assets rose 15.57% year-over-year to $152206.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $583445.0 (up 17.68% YoY) and the FY2025 annual result came in at $145087.0, up 8.65% from the prior year.
- Non-Current Assets improved to $152206.0 in Q1 2026 per BIXT's latest filing, from $145087.0 in the prior quarter.
- Over five years, Non-Current Assets peaked at $152206.0 in Q1 2026 and troughed at $67548.0 in Q2 2022.
- A 5-year average of $111016.5 and a median of $115031.0 in 2024 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2025: Non-Current Assets surged 292.26% in 2022, then advanced 8.65% in 2025.
- Over 5 years, Non-Current Assets stood at $75535.0 in 2022, then soared by 47.68% to $111552.0 in 2023, then grew by 19.71% to $133540.0 in 2024, then gained by 8.65% to $145087.0 in 2025, then advanced by 4.91% to $152206.0 in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $152206.0, $145087.0, and $141795.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 938.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 468.65 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 18.06 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 6.80 Bn |
| 10 | Bioxytran | 2.47 Mn | 2.22 Mn | - | 156,009.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 152,206.00 |
| Dec 31, 2025 | 145,087.00 |
| Sep 30, 2025 | 141,795.00 |
| Jun 30, 2025 | 144,357.00 |
| Mar 31, 2025 | 131,704.00 |
| Dec 31, 2024 | 133,540.00 |
| Sep 30, 2024 | 124,336.00 |
| Jun 30, 2024 | 115,031.00 |
| Mar 31, 2024 | 115,516.00 |
| Dec 31, 2023 | 111,552.00 |
| Sep 30, 2023 | 108,770.00 |
| Jun 30, 2023 | 97,880.00 |
| Mar 31, 2023 | 79,732.00 |
| Dec 31, 2022 | 75,535.00 |
| Sep 30, 2022 | 74,349.00 |
| Jun 30, 2022 | 67,548.00 |
| Mar 31, 2022 | 68,343.00 |
| Dec 31, 2021 | 46,932.00 |
| Sep 30, 2021 | 18,954.00 |
| Jun 30, 2021 | 18,954.00 |